Cystic fibrosis in Canada: A historical perspective

References

• Crozier DN. Cystic fibrosis: a not-so-fatal disease. Pediatr Clin North Am. 1974;21(4):935–950.
   Web of Science ®Google Scholar
• MacLusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol. 1989;7(1):42–48. doi:10.1002/ppul.1950070110.
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis Canada. The Canadian Cystic Fibrosis Registry: 2016 Annual Data Report. Toronto; 2017.
   Google Scholar
• Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245(4922):1073–1080. doi:10.1126/science.2570460.
   PubMed Web of Science ®Google Scholar
• Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245(4922):1066–1073. doi:10.1126/science.2475911.
   PubMed Web of Science ®Google Scholar
• Rommens J, Iannuzzi M, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989;245(4922):1059–1065. doi:10.1126/science.2772657.
   PubMed Web of Science ®Google Scholar
• Collins FS. Positional cloning moves from perditional to traditional. Nat Genet. 1995;9(4):347–350. doi:10.1038/ng0495-347.
   Web of Science ®Google Scholar
• Cystic Fibrosis Mutation Database. 2017. http://www.genet.sickkids.on.ca. Accessed December 21, 2017.
   Google Scholar
• Cystic Fibrosis Foundation. 1976 Report on Survival Studies of Patients with Cystic Fibrosis. Atlanta; 1978.
   Google Scholar
• Dupuis A, Hamilton D, Cole DEC, Corey M. Cystic fibrosis birth rates in Canada: a decreasing trend since the onset of genetic testing. J Pediatr. 2005;147(3):312–315. doi:10.1016/j.jpeds.2005.06.043.
   Web of Science ®Google Scholar
• Cystic Fibrosis Canada. The Canadian Cystic Fibrosis Registry: 2016 Annual Data Report. Toronto; 2017.
   Google Scholar
• Quinton PM. Physiological basis of cystic fibrosis: a historical perspective. Physiol Rev. 1999;79(1Suppl):S3–S22. doi:10.1203/00006450-198502000-00004.
   Google Scholar
• Littlewood JM. History of Cystic Fibrosis. In: Hodson M, Geddes D, Bush A, eds. Hodson and Geddes’ Cystic Fibrosis, 3rd ed. Third edit. Boca Raton, FL: CRC Press; 2012:3–19.
   Google Scholar
• Rochholz EL. The child will soon die whose brow tastes salty when kissed. In: Weber JJ, ed. Almanac of Children’s Songs and Games from Switzerland. Leipzig: JJ Weber; 1857:280.
   Google Scholar
• Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child. 1938;56(2):344. doi:10.1001/archpedi.1938.01980140114013.
   Google Scholar
• Simmonds NJ, Cullinan P, Hodson ME. Growing old with cystic fibrosis—the characteristics of long-term survivors of cystic fibrosis. Respir Med. 2009;103(4):629–635. doi:10.1016/j.rmed.2008.10.011.
   Web of Science ®Google Scholar
• Andersen DH, Hodges RG. Celiac syndrome: V. genetics of cystic fibrosis of the pancreas with a consideration of etiology. Am J Dis Child. 1946;72(1):62–80. doi:10.1001/archpedi.1946.02020300069004.
   Google Scholar
• Matthews LW, Doershuk CF, Wise M, Eddy G, Nudelman H, Spector S. A therapeutic regimen for patients with cystic fibrosis. J Pediatr. 1964;65(4):558–575. doi:http://dx.doi.org/10.1016/S0022-3476(64)80290-0.
   Web of Science ®Google Scholar
• Bau SK, Aspin N, Wood DE, Levison H. The measurement of fluid deposition in humans following mist tent therapy. Pediatrics. 1971;48(4):605–612.
   Web of Science ®Google Scholar
• Chang N, Levison H, Cunningham K, Crozier DN, Grosett O. An evaluation of nightly mist tent therapy for patients with cystic fibrosis. Am Rev Respir Dis. 1973;107(4):672–675.
   Google Scholar
• Bureau MA, McDougall DM, Beaudry PH, Belmonte MM. Late effect of nocturnal mist tent therapy related to the severity of airway obstruction in children with cystic fibrosis. Pediatrics. 1978;61(6):842–846.
   Web of Science ®Google Scholar
• Crozier DN. Cystic fibrosis: a not-so-fatal disease. Pediatr Clin North Am. 1974;21(4):935–950.
   Web of Science ®Google Scholar
• Costa M, Potvin S, Berthiaume Y, et al. Diabetes: a major co-morbidity of cystic fibrosis. Diabetes Metab. 2005;31(3):221–232. doi:10.1016/S1262-3636(07)70189-1.
   Web of Science ®Google Scholar
• McIntosh ID. Health Human Resources Guidelines: Minimum Staffing Standards and Role Descriptions for Canadian Cystic Fibrosis Healthcare Teams. Can Respir J. 2016;2016:1. Epub. doi:10.1155/2016/6369704.
   Web of Science ®Google Scholar
• Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol. 1988;41(6):583–591. doi:10.1016/0895-4356(88)90063-7.
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis Canada. 2013 Annual Report: The Canadian Cystic Fibrosis Registry. Toronto: Cystic Fibrosis Canada; 2015.
   Google Scholar
• Littlewood JM, Smye SW, Cunliffe H. Aerosol antibiotic treatment in cystic fibrosis. Arch Dis Child. 1993;68(6):788–792.
   Web of Science ®Google Scholar
• Stephens D, Garey N, Isles A, Levison H, Gold R. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr Infect Dis. 1983;2(3):209–211.
   PubMedGoogle Scholar
• MacLusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol. 1989;7(1):42–48. doi:10.1002/ppul.1950070110.
   PubMed Web of Science ®Google Scholar
• Stephenson AL, Sykes J, Berthiaume Y, et al. Clinical and demographic factors associated with post-lung transplantation survival in individuals with cystic fibrosis. J Hear Lung Transplant. 2015;34(9):1139–1145. doi:10.1016/j.healun.2015.05.003.
   PubMed Web of Science ®Google Scholar
• Cypel M, Yeung JC, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med. 2011;364(15):1431–1440. doi:10.1056/NEJMoa1014597.
   PubMed Web of Science ®Google Scholar
• Cypel M, Liu M, Rubacha M, et al. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med. 2009;1(4):4ra9. doi:10.1126/scitranslmed.3000266.
   Web of Science ®Google Scholar
• Barbas AS, Dib MJ, Al-Adra DP, et al. Combined lung-liver-pancreas transplantation in a recipient with cystic fibrosis. J Cyst Fibros. 2018;17 (1):e1–30158. doi:10.1016/j.jcf.2017.05.004.
   PubMedGoogle Scholar
• Cypel M, Waddell T, Singer LG, et al. Bilateral pneumonectomy to treat uncontrolled sepsis in a patient awaiting lung transplantation. J Thorac Cardiovasc Surg. 2017;153(4):e67–e69. doi:10.1016/j.jtcvs.2016.11.031.
   Web of Science ®Google Scholar
• Isles A, Maclusky I, Corey M, et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr. 1984;104(2):206–210. doi:10.1016/S0022-3476(84)80993-2.
   PubMed Web of Science ®Google Scholar
• Fung SK, Dick H, Devlin H, Tullis E. Transmissibility and infection control implications of Burkholderia cepacia in cystic fibrosis. Can J Infect Dis. 1998;9(3):177–182.
   Google Scholar
• Pegues DA, Carson LA, Tablan OC, et al. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. J Pediatr. 1994;124(5):694–702. doi:10.1016/S0022-3476(05)81357-5.
   Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Ramotar K, et al. Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. JAMA. 2010;304(19):2145–2153. doi:10.1001/jama.2010.1665.
   PubMed Web of Science ®Google Scholar
• Saiman L, Siegel JD, LiPuma JJ, et al. Infection Prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol. 2014;35(S1):S1–S67. doi:10.1086/676882.
   PubMed Web of Science ®Google Scholar
• Speert DP, Henry D, Vandamme P, Corey M, Mahenthiralingam E. Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. Emerging Infect Dis. 2002;8(2):181–187.
   Web of Science ®Google Scholar
• Henry DA, Campbell ME, LiPuma JJ, Speert DP. Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J Clin Microbiol. 1997;35(3):614–619.
   Web of Science ®Google Scholar
• Peeters C, Zlosnik JEA, Spilker T, Hird TJ, LiPuma JJ, Vandamme P. Burkholderia pseudomultivorans sp. nov., a novel Burkholderia cepacia complex species from human respiratory samples and the Rhizosphere. Syst Appl Microbiol. 2013;36(7):483–489.
   PubMed Web of Science ®Google Scholar
• Vandamme P, Peeters C, Smet B, De, et al. Comparative genomics of Burkholderia singularis sp. nov., a Low G + C content, free-living bacterium that defies taxonomic dissection of the genus Burkholderia. Front Microbiol. 2017;8(September):1–14. doi:10.3389/fmicb.2017.01679.
   Google Scholar
• Cystic Fibrosis Foundation. 1976 Report on Survival Studies of Patients with Cystic Fibrosis. Atlanta; 1978.
   Google Scholar
• Goss C, Sykes J, Stanojevic S, et al. Comparison of nutrition and lung function outcomes in patients with cystic fibrosis living in Canada and the United States. Am J Respir Crit Care Med. 2017;197(6):768–775. doi:10.1164/rccm.201707-1541OC.
   Web of Science ®Google Scholar
• Flume PA, Mogayzel PJJ, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med. 2010;182(3):298–306.
   PubMed Web of Science ®Google Scholar
• Mogayzel PJJ, Naureckas ET, Robinson KA, et al. Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Annals Ats. 2014;11(10):1640–1650.
   Google Scholar
• Smyth AR, Bell SC, Bojcin S, et al. European cystic fibrosis society standards of care: best practice guidelines. J Cyst Fibros. 2014;13:S23–S42.
   PubMed Web of Science ®Google Scholar
• Lands LC, Milner R, Cantin AM, Manson D, Corey M. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr. 2007;151(3):249–254.
   PubMed Web of Science ®Google Scholar
• McIlwaine MP, Alarie N, Davidson GF, et al. Long-term multicentre randomised controlled study of high frequency chest wall oscillation versus positive expiratory pressure mask in cystic fibrosis. Thorax. 2013;68(8):746–751.
   PubMed Web of Science ®Google Scholar
• Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551DCFTR mutation. N Engl J Med. 2010;363(21):1991–2003. doi:10.1056/NEJMoa0909825.
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Davies J, McElvaney G, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663–1672. doi:10.1056/NEJMoa1105185.
   PubMed Web of Science ®Google Scholar
• Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220–231. doi:10.1056/NEJMoa1409547.
   PubMed Web of Science ®Google Scholar
• Ratjen F, Hug C, Marigowda G, et al. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2017;5(7):557–567. doi:10.1016/S2213-2600(17)30215-1.
   PubMed Web of Science ®Google Scholar
• Tsui L, Buchwald M, Barker D, et al. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science. 1985;230(4729):1054–1057. doi:10.1126/science.2997931.
   PubMed Web of Science ®Google Scholar
• Tsui LC, Buetow K, Buchwald M. Genetic analysis of cystic fibrosis using linked DNA Markers. Am J Hum Genet. 1986;39(6):720–728.
   Web of Science ®Google Scholar
• Knowlton RG, Cohen-Haguenauer O, Van Cong N, et al. A polymorphic DNA marker linked to cystic fibrosis is located on chromosome 7. Nature. 1985;318(6044):380–382. http://www.ncbi.nlm.nih.gov/pubmed/2999611.
   Web of Science ®Google Scholar
• White R, Woodward S, Leppert M, et al. A closely linked genetic marker for cystic fibrosis. Nature. 1985;318(6044):382–384. doi:10.1038/318382a0.
   Web of Science ®Google Scholar
• Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245(4922):1073–1080. doi:10.1126/science.2570460.
   PubMed Web of Science ®Google Scholar
• Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066–1073. doi:10.1126/science.2475911.
   PubMed Web of Science ®Google Scholar
• Rommens J, Iannuzzi M, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245(4922):1059–1065. doi:10.1126/science.2772657.
   PubMed Web of Science ®Google Scholar
• Collins FS. Positional cloning moves from perditional to traditional. Nat Genet. 1995;9(4):347–350. doi:10.1038/ng0495-347.
   Web of Science ®Google Scholar
• Cystic Fibrosis Mutation Database. 2017. http://www.genet.sickkids.on.ca. Accessed December 21, 2017.
   Google Scholar
• Bear CE, Li CH, Kartner N, et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell. 1992;68(4):809–818. doi:0092-8674(92)90155-6 [pii] ET - 1992/02/21.
   PubMed Web of Science ®Google Scholar
• Li C, Ramjeesingh M, Reyes E, et al. The cystic fibrosis mutation (ΔF508) does not influence the chloride channel activity of CFTR. Nat Genet. 1993;3(4):311–316. doi:10.1038/ng0493-311.
   Web of Science ®Google Scholar
• Kent G, Oliver M, Foskett JK, et al. Phenotypic abnormalities in long-term surviving cystic fibrosis mice. Pediatr Res. 1996;40(2):233–241. doi:10.1203/00006450-199608000-00008.
   Web of Science ®Google Scholar
• Kent G, Iles R, Bear CE, et al. Lung disease in mice with cystic fibrosis. J Clin Invest. 1997;100(12):3060–3069. doi:10.1172/JCI119861.
   Web of Science ®Google Scholar
• Ramjeesingh M, Li C, Garami E, et al. A novel procedure for the efficient purification of the cystic fibrosis transmembrane conductance regulator (CFTR). Biochem J. 1997;327(1):17–21. (Pt
   Google Scholar
• Rozmahe R, Wilschanski M, Matin A, et al. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet. 1996;12(3):280–287.
   Web of Science ®Google Scholar
• Zielenski J, Corey M, Rozmahel R, et al. Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat Genet. 1999;22(2):128–129.
   Web of Science ®Google Scholar
• Drumm ML, Konstan MW, Schluchter MD, et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med. 2005;353(14):1443–1453. doi:10.1056/NEJMoa051469.
   PubMed Web of Science ®Google Scholar
• Dorfman R, Sandford A, Taylor C, et al. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest. 2008;118(3):1040–1049. doi:10.1172/TGF-.
   Web of Science ®Google Scholar
• Wright FA, Strug LJ, Doshi VK, et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet. 2011;43(6):539–546. doi:10.1038/ng.838.Genome-wide.
   PubMed Web of Science ®Google Scholar
• Blackman SM, Commander CW, Watson C, et al. Genetic modifiers of cystic fibrosis—related diabetes. Diabetes. 2013;62(10):3627–3635. doi:10.2337/db13-0510.
   Web of Science ®Google Scholar
• Gallins PJ, Pace RG, Corvol H, et al. Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis. Nat Commun. 2015;6(1):8382. doi:10.1038/ncomms9382.
   Google Scholar
• Strug LJ, Gonska T, He G, et al. Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics. Hum Mol Genet. 2016;25(20):4590–4600.
   PubMed Web of Science ®Google Scholar
• Koehler DR, Sajjan U, Chow Y-H, et al. Protection of Cftr knockout mice from acute lung infection by a helper-dependent adenoviral vector expressing Cftr in airway epithelia. Proc Natl Acad Sci USA. 2003;100(26):15364–15369. doi:10.1073/pnas.2436478100.
   Web of Science ®Google Scholar
• Hanrahan JW, Matthes E, Carlile G, Thomas DY. Corrector combination therapies for F508del-CFTR. Curr Opin Pharmacol. 2017;34:105–111.
   PubMed Web of Science ®Google Scholar
• Mak DYF, Sykes J, Stephenson AL, Lands LC. The benefits of newborn screening for cystic fibrosis: The Canadian experience. J Cyst Fibros. 2016;15(3):302–308. doi:10.1016/j.jcf.2016.04.001.
   Web of Science ®Google Scholar
• Stephenson AL, Sykes J, Stanojevic S, et al. Survival comparison of patients with cystic fibrosis in Canada and the United States: a population-based cohort study. Ann Intern Med. 2017;166(8):537–546.
   PubMed Web of Science ®Google Scholar